Clinical Trial

Study of AHB-137 in Chronic Hepatitis B (CHB) Participants in North America and Europe Regions

Study acronym: ASPIRE-202
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is a randomized, open-label, multicenter phase 2 clinical trial to evaluate the efficacy and safety of AHB-137 injection in participants with CHB treated with Nucleos(t)ide Analogue (NAs).
Protocol Amendment History 2 changes
critical Recruitment opened 2026-08-07
notable Primary completion pushed: 2027-03-24 -> 2027-05-11 2026-08-07
Trial Details
NCT Number NCT07654283
Lead Sponsor AusperBio Therapeutics Inc.
Conditions Hepatitis B, Chronic
Enrollment 70 participants
Start Date 2026-08-04
Primary Completion 2027-05-11 (estimated)
Study Completion 2028-07-26 (estimated)
Updated on ClinicalTrials.gov 2026-08-06